fbpx
alopecia areata

Individuals who have a diagnosis of severe alopecia areata (AA) may qualify for this clinical research trial and receive investigational oral medication (Upadacitinib) or placebo.

  • Age: ≥ 12 years and ≤ 65 years old
  • 50% or more scalp hair loss
  • Current AA episode less than 8 years
  • No spontaneous scalp hair regrowth over the past 6 months

Patients will be asked to visit the clinic about 16 times over approximately 160 weeks. There is no cost to participate, and participants will be reimbursed for their time and travel.

For further information on the study, please follow the link:

Study Details | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata | ClinicalTrials.gov

Trial ID: NCT06012240

We are actively recruiting for this study. If you are interested and would like to participate in this clinical trial, please submit your details and our team will be in touch when it becomes available: expression of interest form

Accreditations & Memberships

Australasian Hair and Wool Research Society
victoria
international academy cosmetic dermatology
european medecines agency
gpce
deakin university
congress dermatology
bellberry limted
australiasian college dermatologists
australian government national health
australian government ip
australian clinical trials
asdr
albinism fellowship australia
aaaf
ahsf
american dermatological association
british association of dermatology
epworth
international society of dermatology
university of melbourne
Book Appointment
Shop